Your browser is no longer supported. Please, upgrade your browser.
Settings
AKTX Akari Therapeutics, Plc daily Stock Chart
AKTX [NASD]
Akari Therapeutics, Plc
Index- P/E- EPS (ttm)-2.33 Insider Own9.46% Shs Outstand15.51M Perf Week-5.41%
Market Cap27.14M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float7.43M Perf Month-5.91%
Income-31.90M PEG- EPS next Q- Inst Own7.60% Short Float2.94% Perf Quarter-8.85%
Sales- P/S- EPS this Y-84.30% Inst Trans-0.92% Short Ratio3.64 Perf Half Y-1.13%
Book/sh0.57 P/B3.07 EPS next Y- ROA-135.40% Target Price5.25 Perf Year-60.05%
Cash/sh- P/C- EPS next 5Y- ROE-231.10% 52W Range1.62 - 5.49 Perf YTD-59.58%
Dividend- P/FCF- EPS past 5Y39.20% ROI- 52W High-68.12% Beta-5.98
Dividend %- Quick Ratio2.00 Sales past 5Y- Gross Margin- 52W Low8.02% ATR0.12
Employees17 Current Ratio2.00 Sales Q/Q- Oper. Margin- RSI (14)44.29 Volatility5.04% 6.41%
OptionableNo Debt/Eq0.00 EPS Q/Q- Profit Margin- Rel Volume0.18 Prev Close1.71
ShortableYes LT Debt/Eq0.00 EarningsNov 19 BMO Payout- Avg Volume59.97K Price1.75
Recom2.00 SMA20-3.34% SMA50-11.58% SMA200-12.95% Volume10,595 Change2.28%
Feb-08-18Initiated B. Riley FBR, Inc. Neutral $3
Sep-22-17Upgrade William Blair Mkt Perform → Outperform
May-31-17Upgrade Chardan Capital Markets Sell → Neutral $6
Apr-17-17Reiterated Chardan Capital Markets Sell $6.50 → $5
Jul-11-16Initiated Chardan Capital Markets Sell $5
Nov-15-18 09:00AM  Akari Announces Coversin Data to be Presented at 2018 Complement-Based Drug Development Summit GlobeNewswire
06:50AM  Akari Announces Third Quarter 2018 Financial Results and Business Highlights GlobeNewswire
Oct-25-18 08:55AM  Factors of Influence in 2018, Key Indicators and Opportunity within Intersect ENT, Akari Therapeutics, Ampio Pharmaceuticals, Virtusa, Umpqua, and Hamilton Lane New Research Emphasizes Economic Growth GlobeNewswire
Sep-30-18 07:30AM  Akari Therapeutics Announces New Clinical Data in Post-Transplant Thrombotic Microangiopathies. Data Supports Akaris Ongoing Clinical Expansion into a Range of Orphan Autoinflammatory Diseases That Are Either Mediated by Complement C5 or Have Synchronous LTB4 and C5 Activity GlobeNewswire
Sep-27-18 06:56AM  Akari Announces Second Quarter 2018 Financial Results and Business Highlights GlobeNewswire +11.97%
06:55AM  Akari Therapeutics Enters into a Securities Purchase Agreement for up to $20 Million with Aspire Capital Fund, LLC GlobeNewswire
Sep-25-18 07:00AM  Akari Therapeutics to Present at the Cantor Fitzgerald Global Healthcare Conference GlobeNewswire
Sep-12-18 07:00AM  Akari Therapeutics Announces New Preclinical Rheumatoid Arthritis Data and New Clinical Data in Patients with Bullous Pemphigoid, Highlighting Potential Advantages of Coversins bifunctional activity inhibiting both the Complement and Leukotriene Inflammatory Pathways GlobeNewswire +7.29%
Sep-04-18 08:30AM  Research Report Identifies Brady, Akari Therapeutics, MTGE Investment, Jones Lang LaSalle, New Relic, and Sorrento Therapeutics with Renewed Outlook Fundamental Analysis, Calculating Forward Movement GlobeNewswire +18.09%
Aug-20-18 09:00AM  The Rosen Law Firm, P.A. Announces Proposed Class Action Settlement on Behalf of Purchasers of Securities of Akari Therapeutics, plc -- AKTX GlobeNewswire
Aug-17-18 07:00AM  Akari Announces First Quarter 2018 Financial Results and Update on its Growing Pipeline of Phase II and Phase III Clinical Trials GlobeNewswire
Jun-15-18 08:00AM  Akari Therapeutics to Present Poster at the 23rd Congress of the European Hematology Association GlobeNewswire +8.99%
May-25-18 07:53PM  How Do Analysts See Akari Therapeutics Plc (NASDAQ:AKTX) Performing In The Years Ahead? Simply Wall St.
08:20AM  Market Trends Toward New Normal in Independent Bank, First Busey, American Public Education, The First Bancshares, Northfield, and Akari Therapeutics Emerging Consolidated Expectations, Analyst Ratings GlobeNewswire
May-21-18 08:00AM  Akari Therapeutics Receives Notice Related to Delay in 20-F Filing GlobeNewswire -6.84%
May-16-18 07:23PM  Should You Buy Akari Therapeutics Plc (NASDAQ:AKTX) Now? Simply Wall St.
Apr-16-18 07:20AM  Blog Exposure - Tetraphase Pharma Announced Data Presentations from IGNITE4 Study at 28th European Congress of Clinical Microbiology and Infectious Diseases ACCESSWIRE -5.74%
Apr-03-18 08:25AM  Analysis: Positioning to Benefit within ForeScout Technologies, CommerceHub, Newtek Business Services, Credit Acceptance, Akari Therapeutics, and Brady Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire
Mar-21-18 03:50PM  Edited Transcript of AKTX earnings conference call or presentation 21-Mar-18 12:30pm GMT Thomson Reuters StreetEvents -6.13%
07:00AM  Akari Therapeutics Announces Fourth Quarter and Full Year 2017 Financial Results and Highlights Recent Clinical Progress GlobeNewswire
Mar-16-18 08:00AM  Akari Therapeutics To Report Fourth Quarter and Full Year 2017 Financial and Operational Results and Host Conference Call on March 21, 2018 GlobeNewswire
Feb-07-18 04:30PM  Akari Therapeutics to Present at the Leerink Partners Global Healthcare Conference GlobeNewswire
Feb-06-18 07:00AM  Akari Therapeutics Announces Completion of Phase II COBALT Trial of Coversin in Patients with PNH and Further Progress of Clinical Trials GlobeNewswire -10.59%
Feb-05-18 07:45AM  Market Trends Toward New Normal in NV5 Global, Akari Therapeutics, American Public Education, Twilio, Monroe Capital, and Jabil Emerging Consolidated Expectations, Analyst Ratings GlobeNewswire -7.09%
Jan-23-18 08:00AM  Akari Therapeutics Strengthens Board with Two Senior Industry Appointments GlobeNewswire
Jan-10-18 08:42AM  Alder BioPharmaceuticals (ALDR) Jumps: Stock Rises 15.5% Zacks
Jan-08-18 08:46AM  CRISPR Therapeutics (CRSP) Jumps: Stock Rises 12.1% Zacks
Jan-05-18 04:29PM  Penumbra (PEN) Forms JV on Virtual Reality in Health Space Zacks -6.00%
08:56AM  Audentes Therapeutics (BOLD) Jumps: Stock Rises 14.9% Zacks
Jan-03-18 03:34PM  New Products Aid Boston Scientific, LOTUS Relaunch Lag Ails Zacks
01:40PM  Thermo Fisher Buys Phenom-World, Aids Analytical Instruments Zacks
03:04AM  Anika Therapeutics Receives FDA Nod for Bone Repair Therapy Zacks
Jan-02-18 09:09AM  PetMed Rides on Solid Reorders & New Orders Amid Competition Zacks
Dec-28-17 09:08AM  NutriSystem (NTRI) Adopts Multi-Brand Strategy for 2018 Zacks
Dec-26-17 08:51AM  Array BioPharma (ARRY) Looks Good: Stock Adds 9.6% in Session Zacks
Dec-21-17 08:58AM  Amarin Corporation (AMRN) in Focus: Stock Moves 8.9% Higher Zacks
Dec-13-17 08:57AM  Syros Pharmaceuticals (SYRS) in Focus: Stock Moves 12.7% Higher Zacks
08:47AM  Tenet Healthcare (THC) in Focus: Stock Moves 8.5% Higher Zacks
Dec-12-17 07:40AM  Wired News Akaris Phase-II COBALT Trial of Coversin in Patients with PNH Met the Primary Endpoint ACCESSWIRE -9.01%
Dec-11-17 08:41AM  Alexion (ALXN) in Focus: Stock Moves 7.2% Higher Zacks
Dec-08-17 04:05PM  Akari Therapeutics Announces Phase II COBALT trial of Coversin in Patients with PNH Met the Primary Endpoint GlobeNewswire
Dec-06-17 08:53AM  Why AveXis (AVXS) Could Be Positioned for a Slump Zacks
Dec-04-17 04:01PM  Akari Therapeutics to Host Investor and Analyst Event During the 59th American Society of Hematology Meeting GlobeNewswire
Dec-01-17 09:33AM  Zacks.com featured highlights: Akari Therapeutics, Joint, Tailored Brands, Ardelyx and BioTime Zacks
Nov-30-17 08:20AM  5 Affordable Breakout Stocks Offering Excellent Returns Zacks
08:00AM  Akari: December Coversin Update, Analysts Opinion and Catalysts ACCESSWIRE
Nov-27-17 08:51AM  ANI Pharmaceuticals (ANIP) Catches Eye: Stock Jumps 17.7% Zacks
Oct-18-17 09:00AM  Akari Therapeutics Announces Pricing of Public Offering of American Depositary Shares GlobeNewswire -29.69%
Oct-17-17 04:01PM  Akari Therapeutics Announces Proposed Public Offering of American Depositary Shares GlobeNewswire
Oct-13-17 07:10AM  Corporate News Blog - Akari Therapeutics Announces Enrolment of Additional Patients in COBALT Phase-II Clinical Trial of Coversin(TM) ACCESSWIRE -8.91%
Oct-12-17 08:20AM  Today's Research Reports on Stocks to Watch: Akari Therapeutics and Seattle Genetics ACCESSWIRE -5.95%
Oct-11-17 07:00AM  Akari Therapeutics Announces Further Clinical Progress GlobeNewswire +22.72%
Sep-22-17 01:42PM  Akari Therapeutics Rally Continues As William Blair Upgrades Benzinga -6.41%
08:25AM  Werner Enterprises, Cott, Akari Therapeutics, and Alexion highlighted as Zacks Bull and Bear of the Day Zacks
08:20AM  Today's Research Reports on Stocks to Watch: Akari Therapeutics and Intercept Pharmaceuticals ACCESSWIRE
Sep-21-17 02:10PM  Akari Therapeutics (AKTX) Stock is Skyrocketing Over 60% Today: Here's Why Zacks +56.35%
07:00AM  Akari Therapeutics Announces Regulatory Progress Following FDA Meeting GlobeNewswire
Sep-19-17 07:00AM  Akari Therapeutics to Present at the Cantor Fitzgerald Global Healthcare Conference GlobeNewswire
Sep-12-17 08:47AM  Idera Pharmaceuticals (IDRA) Jumps: Stock Rises 14.4% Zacks +21.62%
Sep-11-17 08:42AM  NewLink Genetics (NLNK) Jumps: Stock Rises 29.9% Zacks +20.25%
Sep-06-17 08:46AM  Regenxbio (RGNX) in Focus: Stock Moves 9.5% Higher Zacks
Aug-21-17 07:05AM  Akari Therapeutics Announces Appointment of David Horn Solomon as CEO GlobeNewswire
Aug-10-17 07:00AM  Akari Therapeutics to Present at the 37th Annual Canaccord Genuity Growth Conference GlobeNewswire -6.70%
Jul-11-17 10:39AM  FINAL DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Akari Therapeutics Plc (AKTX) and Lead Plaintiff Deadline - - July 11, 2017 Accesswire
Jul-10-17 10:50PM  AKARI THERAPEUTICS 24 HOUR DEADLINE ALERT: APPROXIMATELY 24 HOURS REMAIN; CLAIMSFILER REMINDS INVESTORS of Deadline in Class Action Lawsuit Against Akari Therapeutics, Plc (AKTX) GlobeNewswire +8.29%
01:07PM  DEADLINE TOMORROW: Khang & Khang LLP Announces a Securities Class Action Lawsuit against Akari Therapeutics, Plc and Reminds Investors with Losses Exceeding $100,000 to Contact the Firm GlobeNewswire
10:10AM  DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Akari Therapeutics Plc (AKTX) & Lead Plaintiff Deadline - July 11, 2017 GlobeNewswire
Jul-07-17 11:58PM  JULY 11 DEADLINE: Lundin Law PC Announces Securities Class Action Lawsuit against Akari Therapeutics, Plc and Encourages Investors with Losses In Excess of $100,000 to Contact the Firm Accesswire -9.44%
10:50PM  AKARI THERAPEUTICS 96 HOUR DEADLINE ALERT: Approximately 96 Hours Remain; Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors of Deadline in Class Action Lawsuit against Akari Therapeutics, Plc (AKTX) Business Wire
07:35PM  SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Akari Therapeutics plc of Class Action Lawsuit and Upcoming Deadline - AKTX PR Newswire
10:38AM  DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Akari Therapeutics Plc (AKTX) and Lead Plaintiff Deadline - - July 11, 2017 Accesswire
10:30AM  July 11 Deadline Alert: GPM Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Akari Therapeutics, Plc Business Wire
Jul-06-17 12:19PM  5-DAY ALERT: Khang & Khang LLP Announces a Securities Class Action Lawsuit against Akari Therapeutics, Plc and Reminds Investors with Losses Exceeding $100,000 to Contact the Firm Accesswire
10:35AM  DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Akari Therapeutics Plc (AKTX) & Lead Plaintiff Deadline - July 11, 2017 Accesswire
Jul-05-17 06:05PM  AKARI LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Akari Therapeutics, Plc To Contact The Firm Business Wire
05:21PM  DEADLINE ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Akari Therapeutics, Plc and Reminds Investors with Losses In Excess of $100,000 to Contact the Firm Accesswire
03:47PM  EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Akari Therapeutics, Plc - AKTX PR Newswire
Jul-04-17 01:00PM  SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Akari Therapeutics plc of Class Action Lawsuit and Upcoming Deadline - AKTX Accesswire
Jul-03-17 03:51PM  EQUITY ALERT: Khang & Khang LLP Announces a Securities Class Action Lawsuit against Akari Therapeutics, Plc and Reminds Investors with Losses Exceeding $100,000 to Contact the Firm Accesswire
10:45AM  INVESTOR ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Akari Therapeutics Plc (AKTX) & Lead Plaintiff Deadline - July 11, 2017 Accesswire
Jun-30-17 11:51PM  APPROACHING DEADLINE: Lundin Law PC Announces Securities Class Action Lawsuit against Akari Therapeutics, Plc and Reminds Investors with Losses In Excess of $100,000 to Contact the Firm Accesswire
10:50PM  AKARI THERAPEUTICS SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Akari Therapeutics, Plc (AKTX) GlobeNewswire
02:58PM  SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Akari Therapeutics plc of Class Action Lawsuit and Upcoming Deadline AKTX GlobeNewswire
10:37AM  INVESTOR ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Akari Therapeutics Plc (AKTX) and Lead Plaintiff Deadline - - July 11, 2017 Accesswire
Jun-29-17 05:18PM  INVESTOR ALERT: Khang & Khang LLP Announces a Securities Class Action Lawsuit against Akari Therapeutics, Plc and Reminds Investors with Losses Exceeding $100,000 to Contact the Firm Accesswire
10:34AM  SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Akari Therapeutics Plc (AKTX) & Lead Plaintiff Deadline - July 11, 2017 Accesswire
Jun-26-17 04:43PM  EQUITY ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Akari Therapeutics, Plc and Reminds Investors with Losses In Excess of $100,000 to Contact the Firm Accesswire
10:36AM  INVESTOR ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Akari Therapeutics Plc (AKTX) and Lead Plaintiff Deadline: July 11, 2017 Accesswire
Jun-23-17 11:59PM  SHAREHOLDER ALERT: Khang & Khang LLP Announces a Securities Class Action Lawsuit against Akari Therapeutics, Plc and Reminds Investors with Losses Exceeding $100,000 to Contact the Firm Accesswire +8.18%
04:48PM  Akari Notice: Rosen Law Firm Reminds Akari Therapeutics, Plc Investors of Important Deadline in Class Action - AKTX GlobeNewswire
07:00AM  Akari Therapeutics to Present Data from Phase 2 PNH Trial of Coversin at the 22nd Congress of the European Hematology Association GlobeNewswire
Jun-22-17 02:16PM  SHAREHOLDER ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Akari Therapeutics, Plc and Reminds Investors with Losses to Contact the Firm Accesswire -5.17%
10:34AM  SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Akari Therapeutics Plc (AKTX) & Lead Plaintiff Deadline: July 11, 2017 Accesswire
Jun-21-17 05:28PM  INVESTOR ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Akari Therapeutics, Plc and Reminds Investors with Losses to Contact the Firm Accesswire +5.89%
10:36AM  INVESTOR ALERT - - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Akari Therapeutics Plc (AKTX) and Lead Plaintiff Deadline: July 11, 2017 Accesswire
Jun-20-17 01:48PM  IMPORTANT EQUITY ALERT: Khang & Khang LLP Announces a Securities Class Action Lawsuit against Akari Therapeutics, Plc and Reminds Investors with Losses to Contact the Firm Accesswire +5.56%
Jun-19-17 05:59PM  AKARI LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Akari Therapeutics, Plc To Contact The Firm Business Wire -5.86%
03:36PM  IMPORTANT EQUITY ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Akari Therapeutics, Plc and Reminds Investors with Losses to Contact the Firm Accesswire
10:35AM  INVESTOR ALERT - - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Akari Therapeutics Plc (AKTX) & Lead Plaintiff Deadline: July 11, 2017 Accesswire
Jun-16-17 10:50PM  AKARI THERAPEUTICS SHAREHOLDER ALERT by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit against Akari Therapeutics, Plc (AKTX) Business Wire +14.90%
Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of treatments for a range of rare and orphan autoimmune and inflammatory diseases. Its lead drug candidate is Coversin, a second-generation complement inhibitor that is in Phase II clinical trial for the treatment of autoimmune and inflammatory diseases, including paroxysmal nocturnal hemoglobinuria, guillain barre syndrome, and atypical hemolytic uremic syndrome. The company is based in New York, New York. Akari Therapeutics, Plc is a subsidiary of RPC Pharma Limited.